Quantcast

Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer meets primary and secondary endpoints

Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.

Read more

Seattle Genetics, Astellas Phase 1 Trial of Investigational Agent Enfortumab Vedotin plus Pembrolizumab met outcomes: 71% patients confirm response.

Seattle Genetics, and Astellas Pharma’s study met outcomes for safety and 71 Percent of patients with locally advanced or metastatic urothelial (bladder) cancer had a confirmed response, the companies presented Saturday at ESMO Congress in Barcelona.

Read more